News articles about NuVasive (NASDAQ:NUVA) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuVasive earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 46.8606912940056 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Spinal Fusion Devices Market: Open Surgery Led the Market in Terms of Revenue (canadianbusinesstribune.com)
- Future Growth of Cell Therapy Market is Growth at a Strong CAGR of 10.6 % till 2023 (medgadget.com)
- NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $260.59 Million (americanbankingnews.com)
- Bone Grafts Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023 (openpr.com)
- Financial Survey: NuVasive (NUVA) versus Cryolife (CRY) (americanbankingnews.com)
Several analysts recently commented on NUVA shares. Needham & Company LLC raised shares of NuVasive from an “underperform” rating to a “buy” rating and set a $71.00 target price for the company in a report on Thursday, January 4th. Zacks Investment Research raised shares of NuVasive from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. BidaskClub raised shares of NuVasive from a “sell” rating to a “hold” rating in a report on Friday, December 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $70.00 price target on shares of NuVasive in a report on Thursday, December 14th. Finally, BTIG Research set a $74.00 price objective on shares of NuVasive and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $68.19.
NuVasive (NASDAQ:NUVA) last posted its quarterly earnings data on Monday, February 26th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.56. The business had revenue of $271.70 million during the quarter, compared to the consensus estimate of $272.11 million. NuVasive had a net margin of 8.06% and a return on equity of 13.40%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same quarter last year, the company posted $0.53 earnings per share. equities research analysts predict that NuVasive will post 2.46 earnings per share for the current year.
In other news, CEO Gregory T. Lucier acquired 6,000 shares of the business’s stock in a transaction dated Tuesday, March 6th. The stock was bought at an average cost of $50.30 per share, for a total transaction of $301,800.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is currently owned by company insiders.
NuVasive Company Profile
Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.